Literature DB >> 34249426

Prognostic stratification based on a novel nomogram for left-sided pancreatic adenocarcinoma after surgical resection: a multi-center study.

Zuyi Ma1,2, Bowen Huang3, Shanzhou Huang1, Chunsheng Liu1,2, Jiasheng Cao4, Zehao Zheng1,2, Zhenchong Li1, Zixuan Zhou1, Hongkai Zhuang1,2, Yiping Zou1,2, Linling Yang5, Junchao Guo3, Chuanzhao Zhang1, Baohua Hou1.   

Abstract

Left-sided pancreatic adenocarcinoma (LPAC) has a poorer prognosis and has some distinct features compared to cancer of pancreatic head. A reliable model to predict the prognosis of LPAC following surgery is needed in clinical practice. Our study included 231 patients with resected LPAC from 3 Chinese pancreatic disease centers. Cox-regression analysis was conducted to identify independent risk factors of LAPC. Then we established a nomogram and performed C-index, receiver operating characteristic curve, calibration plot and decision curve analysis to assess its discrimination and calibration. As a result, CA19-9, surgical margin, tumor differentiation, lymph node metastasis, and postoperative adjuvant chemotherapy were identified as significant prognostic factors. Based on these predictors, a novel nomogram was constructed. The nomogram achieved high C-indexes in the training cohort (0.805) and validation cohort (0.719), which were superior than the AJCC-8 staging system and other nomograms. The area under curve of the nomogram for predicting patients survival at 1-, 2-, and 3-year in training cohort were more than 0.8. Kaplan-Meier survival curve for the subgroups stratified based on the nomogram showed a better separation than the AJCC-8 stage I, II, III, indicating a superior ability of risk stratification for our model. In summary, we constructed a nomogram which showed a better predictive ability for patients' survival with LPAC after surgical resection than the AJCC staging system and other predictive models. Our model would be helpful to discriminate high-risk LPAC and facilitate clinical decision making. AJCR
Copyright © 2021.

Entities:  

Keywords:  Left-sided pancreatic adenocarcinoma; nomogram; overall survival; prognostic stratification

Year:  2021        PMID: 34249426      PMCID: PMC8263662     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  29 in total

1.  Genomic analyses identify molecular subtypes of pancreatic cancer.

Authors:  Peter Bailey; David K Chang; Katia Nones; Amber L Johns; Ann-Marie Patch; Marie-Claude Gingras; David K Miller; Angelika N Christ; Tim J C Bruxner; Michael C Quinn; Craig Nourse; L Charles Murtaugh; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Ehsan Nourbakhsh; Shivangi Wani; Lynn Fink; Oliver Holmes; Venessa Chin; Matthew J Anderson; Stephen Kazakoff; Conrad Leonard; Felicity Newell; Nick Waddell; Scott Wood; Qinying Xu; Peter J Wilson; Nicole Cloonan; Karin S Kassahn; Darrin Taylor; Kelly Quek; Alan Robertson; Lorena Pantano; Laura Mincarelli; Luis N Sanchez; Lisa Evers; Jianmin Wu; Mark Pinese; Mark J Cowley; Marc D Jones; Emily K Colvin; Adnan M Nagrial; Emily S Humphrey; Lorraine A Chantrill; Amanda Mawson; Jeremy Humphris; Angela Chou; Marina Pajic; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Lovell; Neil D Merrett; Christopher W Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Kim Moran-Jones; Nigel B Jamieson; Janet S Graham; Fraser Duthie; Karin Oien; Jane Hair; Robert Grützmann; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Borislav Rusev; Paola Capelli; Roberto Salvia; Giampaolo Tortora; Debabrata Mukhopadhyay; Gloria M Petersen; Donna M Munzy; William E Fisher; Saadia A Karim; James R Eshleman; Ralph H Hruban; Christian Pilarsky; Jennifer P Morton; Owen J Sansom; Aldo Scarpa; Elizabeth A Musgrove; Ulla-Maja Hagbo Bailey; Oliver Hofmann; Robert L Sutherland; David A Wheeler; Anthony J Gill; Richard A Gibbs; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers.

Authors:  Yun Shin Chun; Timothy M Pawlik; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2017-07-27       Impact factor: 5.344

Review 4.  Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.

Authors:  Guopei Luo; Kaizhou Jin; Shengming Deng; He Cheng; Zhiyao Fan; Yitao Gong; Yunzhen Qian; Qiuyi Huang; Quanxing Ni; Chen Liu; Xianjun Yu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-08-19       Impact factor: 10.680

Review 5.  Early Detection of Pancreatic Cancer: Opportunities and Challenges.

Authors:  Aatur D Singhi; Eugene J Koay; Suresh T Chari; Anirban Maitra
Journal:  Gastroenterology       Date:  2019-02-02       Impact factor: 22.682

6.  Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States.

Authors:  Melvin K Lau; Jessica A Davila; Yasser H Shaib
Journal:  Pancreas       Date:  2010-05       Impact factor: 3.327

7.  Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.

Authors:  Amr I Al Abbas; Mazen Zenati; Caroline J Reiser; Ahmad Hamad; Jae Pil Jung; Amer H Zureikat; Herbert J Zeh; Melissa E Hogg
Journal:  Ann Surg Oncol       Date:  2020-01-02       Impact factor: 5.344

8.  Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.

Authors:  Kelvin K W Chan; Helen Guo; Sierra Cheng; Jaclyn M Beca; Ruby Redmond-Misner; Wanrudee Isaranuwatchai; Lucy Qiao; Craig Earle; Scott R Berry; James J Biagi; Stephen Welch; Brandon M Meyers; Nicole Mittmann; Natalie Coburn; Jessica Arias; Deborah Schwartz; Wei F Dai; Scott Gavura; Robin McLeod; Erin D Kennedy
Journal:  Cancer Med       Date:  2019-11-13       Impact factor: 4.452

9.  Defining the molecular pathology of pancreatic body and tail adenocarcinoma.

Authors:  S B Dreyer; N B Jamieson; R Upstill-Goddard; P J Bailey; C J McKay; A V Biankin; D K Chang
Journal:  Br J Surg       Date:  2018-01       Impact factor: 6.939

10.  Development of a Nomogram to Predict Disease-Specific Survival for Patients After Resection of a Non-Metastatic Adenocarcinoma of the Pancreatic Body and Tail.

Authors:  Yiping Zou; Hongwei Han; Shiye Ruan; Zhixiang Jian; Liang Jin; Yuanpeng Zhang; Zhihong Chen; Zi Yin; Zuyi Ma; Haosheng Jin; Menghua Dai; Ning Shi
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.